PE20150928A1 - 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia - Google Patents

1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Info

Publication number
PE20150928A1
PE20150928A1 PE2015000596A PE2015000596A PE20150928A1 PE 20150928 A1 PE20150928 A1 PE 20150928A1 PE 2015000596 A PE2015000596 A PE 2015000596A PE 2015000596 A PE2015000596 A PE 2015000596A PE 20150928 A1 PE20150928 A1 PE 20150928A1
Authority
PE
Peru
Prior art keywords
treatment
indanes
deuterated
fenyl
schizophrenia
Prior art date
Application number
PE2015000596A
Other languages
English (en)
Inventor
Morten Jorgensen
Peter Hongaard Andersen
Klaus Gjervig Jensen
Mette Graulund Hvenegaard
Lassina Badolo
Mikkel Fog Jacobsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of PE20150928A1 publication Critical patent/PE20150928A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere a 1-piperazino-3-fenil-indanos deuterados de formula (Y); y sus sales con actividad en receptores dopaminicos D1 y D2, asi como los receptores de 5HT2 en el sistema nervioso central, a medicamentos que comprenden tales compuestos como ingredientes activos, al uso de tales compuestos en el tratamiento de enfermedades en el sistema nervioso central y a metodos de tratamiento que comprenden la administracion de tales compuestos
PE2015000596A 2011-06-20 2012-06-19 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia PE20150928A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498651P 2011-06-20 2011-06-20
US201161537103P 2011-09-21 2011-09-21

Publications (1)

Publication Number Publication Date
PE20150928A1 true PE20150928A1 (es) 2015-06-26

Family

ID=46682855

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015000596A PE20150928A1 (es) 2011-06-20 2012-06-19 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
PE2013002857A PE20141113A1 (es) 2011-06-20 2012-06-19 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2013002857A PE20141113A1 (es) 2011-06-20 2012-06-19 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia

Country Status (40)

Country Link
US (8) US8575174B2 (es)
EP (4) EP3135656B1 (es)
JP (1) JP5668177B2 (es)
KR (2) KR101939546B1 (es)
CN (1) CN103649019B (es)
AP (1) AP3310A (es)
AR (1) AR086987A1 (es)
AU (1) AU2012273657B2 (es)
BR (1) BR112013031702B1 (es)
CA (1) CA2837820C (es)
CL (1) CL2013003646A1 (es)
CO (1) CO6821965A2 (es)
CR (1) CR20130654A (es)
CY (2) CY1118158T1 (es)
DK (2) DK2720989T3 (es)
DO (1) DOP2013000305A (es)
EA (1) EA024651B1 (es)
EC (1) ECSP14013155A (es)
ES (3) ES2719145T3 (es)
GE (1) GEP201706655B (es)
GT (1) GT201300304A (es)
HK (1) HK1197228A1 (es)
HR (2) HRP20161348T1 (es)
HU (2) HUE030883T2 (es)
IL (1) IL229640B (es)
JO (1) JO3128B1 (es)
LT (2) LT3135656T (es)
MA (1) MA35268B1 (es)
MD (1) MD4538C1 (es)
ME (2) ME03375B (es)
MX (1) MX339552B (es)
MY (1) MY196998A (es)
PE (2) PE20150928A1 (es)
PL (2) PL3135656T3 (es)
PT (2) PT3135656T (es)
RS (2) RS55304B1 (es)
SI (2) SI3135656T1 (es)
SM (1) SMT201600383B (es)
TW (3) TWI614234B (es)
WO (1) WO2012176066A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012176066A1 (en) * 2011-06-20 2012-12-27 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
JP7266022B2 (ja) 2017-09-07 2023-04-27 大塚製薬株式会社 ピペリジン誘導体のピペリジン窒素を重水素低級アルキルでモノアルキル化する工業的製造方法
CN112930341A (zh) * 2018-10-29 2021-06-08 H.隆德贝克有限公司 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐
US11535600B2 (en) 2018-12-03 2022-12-27 H. Lundbeck A/S Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
CA3124399A1 (en) * 2018-12-21 2020-06-25 Concert Pharmaceuticals, Inc. Deuterated forms and derivatives of volinanserin
WO2020184670A1 (ja) * 2019-03-13 2020-09-17 大塚製薬株式会社 二級アミンを含有する化合物のアミン部分に重水素低級アルキルを導入する方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196284A (en) 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
GB8427125D0 (en) 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
KR910003427B1 (ko) 1984-12-04 1991-05-31 산도즈 파마슈티칼스 코포레이션 메발로노락톤의 인덴동족체 및 이들의 유도체의 제법
DK286990D0 (da) 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
WO1999015524A1 (en) 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
ES2383369T3 (es) * 2003-08-18 2012-06-20 H. Lundbeck A/S Sales de succinato y malonato de TRANS-4-((1R,3S)-6-CLORO-3-FENILINDAN-1-IL)-1,2,2-TRIMETILPIPERAZINA y el uso como medicamento
DK1773772T3 (da) 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission
RU2366654C2 (ru) 2004-06-08 2009-09-10 ЭнЭсЭйБи, ФИЛИАЛ АФ НЕУРОСЕРЧ СВИДЕН АБ, СВЕРИЙЕ Новые дизамещенные фенилпиперидины/пиперазины в качестве модуляторов допаминовой нейротрансмиссии
TWI376373B (en) * 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
MX2007009816A (es) 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
ES2396365T3 (es) 2005-07-29 2013-02-21 Concert Pharmaceuticals Inc. Nuevos derivados de benzo[D][1,3]-dioxol deuterados como inhibidores de la recaptación de serotonina
DK1954669T3 (en) 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
JP4986462B2 (ja) 2006-01-27 2012-07-25 シャープ株式会社 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
WO2008086158A1 (en) 2007-01-04 2008-07-17 Smithkline Beecham Corporation Benzodihydroquinazoline as pi3 kinase inhibitors
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
EP1997479A1 (en) 2007-05-31 2008-12-03 Helm AG Stabilized amorphous candesartan cilexetil compositions for oral administration
BRPI0823520A2 (pt) 2007-06-12 2013-12-17 Concert Pharmaceuticals Inc Composto derivado de azapeptídeos e composição farmacêutica contendo o mesmo
US20090062303A1 (en) 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched ziprasidone
AU2009243813B2 (en) 2008-05-07 2014-05-29 H. Lundbeck A/S Method for treating cognitive deficits
KR20110081176A (ko) 2008-10-03 2011-07-13 하. 룬드벡 아크티에셀스카브 경구용 제형물
KR20110110097A (ko) 2008-10-28 2011-10-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 수난용성 성분을 위한 메조포러스 물질 부형제
EP2362865A2 (en) 2008-10-28 2011-09-07 Concert Pharmaceuticals Inc. Deuterated 2-propylpentanoic acid compounds
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
US8557994B2 (en) 2009-07-27 2013-10-15 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US8658236B2 (en) * 2009-08-21 2014-02-25 Deuteria Beverages, Llc Alcoholic compositions having a lowered risk of acetaldehydemia
KR101149529B1 (ko) 2009-09-11 2012-05-25 한국화학연구원 인덴온 유도체 및 이를 포함하는 약학적 조성물
CN102020522A (zh) * 2009-09-21 2011-04-20 陈松源 氘代药物的制备方法和应用
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2639216B1 (en) 2010-11-09 2018-07-11 Kaneka Corporation Halogenated indenones and method for producing optically active indanones or optically active indanols by using same
JP2014501771A (ja) 2011-01-07 2014-01-23 ハー・ルンドベック・アクチエゼルスカベット ４−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン−１−イル）−１，２，２−トリメチル−ピペラジンと１−（（１ｒ，３ｓ）−６−クロロ−３−フェニル−インダン，１−イル）−３，３−ジメチル−ピペラジンとを分割するための方法
WO2012137225A1 (en) 2011-04-08 2012-10-11 Sphaera Pharma Pvt. Ltd Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
WO2012176066A1 (en) * 2011-06-20 2012-12-27 H. Lundbeck A/S Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
US9487500B2 (en) 2012-10-04 2016-11-08 Inhibikase Therapeutics, Inc. Compounds and compositions thereof
AR094054A1 (es) 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma

Also Published As

Publication number Publication date
HRP20190593T1 (hr) 2019-05-17
EP3135656B1 (en) 2019-02-27
CA2837820C (en) 2019-02-19
MD20140004A2 (en) 2014-05-31
KR101939546B1 (ko) 2019-01-16
BR112013031702A2 (pt) 2016-12-13
PT2720989T (pt) 2016-11-07
US9012453B2 (en) 2015-04-21
RS55304B1 (sr) 2017-03-31
DOP2013000305A (es) 2014-02-28
EP4215512A1 (en) 2023-07-26
BR112013031702B1 (pt) 2021-11-03
ES2939477T3 (es) 2023-04-24
US9617231B2 (en) 2017-04-11
TW201722895A (zh) 2017-07-01
US12116355B2 (en) 2024-10-15
US20160068497A1 (en) 2016-03-10
US10501427B2 (en) 2019-12-10
DK2720989T3 (en) 2016-11-28
NZ618222A (en) 2015-03-27
LT3135656T (lt) 2019-04-25
IL229640B (en) 2018-02-28
DK3135656T3 (en) 2019-04-23
AR086987A1 (es) 2014-02-05
WO2012176066A1 (en) 2012-12-27
JO3128B1 (ar) 2017-09-20
CY1118158T1 (el) 2017-06-28
ME02513B (me) 2017-02-20
GT201300304A (es) 2015-01-16
HK1197228A1 (zh) 2015-01-09
PT3135656T (pt) 2019-05-03
EA024651B1 (ru) 2016-10-31
SI2720989T1 (sl) 2016-11-30
PE20141113A1 (es) 2014-09-25
EP2720989A1 (en) 2014-04-23
HUE044043T2 (hu) 2019-09-30
TW201311248A (zh) 2013-03-16
AU2012273657A1 (en) 2013-12-12
AP2013007338A0 (en) 2013-12-31
MD4538B1 (ro) 2017-12-31
CR20130654A (es) 2014-03-24
MX2013014849A (es) 2014-03-31
CN103649019A (zh) 2014-03-19
AU2012273657B2 (en) 2016-07-21
EP3508468B1 (en) 2023-01-18
GEP201706655B (en) 2017-04-25
ECSP14013155A (es) 2014-02-28
US20150307458A1 (en) 2015-10-29
ME03375B (me) 2020-01-20
EP3135656A1 (en) 2017-03-01
TWI614234B (zh) 2018-02-11
TW201902481A (zh) 2019-01-16
LT2720989T (lt) 2016-11-25
MD4538C1 (ro) 2018-07-31
US20200131143A1 (en) 2020-04-30
CN103649019B (zh) 2015-09-16
EP3508468A1 (en) 2019-07-10
ES2719145T3 (es) 2019-07-08
CA2837820A1 (en) 2012-12-27
MA35268B1 (fr) 2014-07-03
TWI627956B (zh) 2018-07-01
AP3310A (en) 2015-06-30
US20170158650A1 (en) 2017-06-08
RS58546B1 (sr) 2019-05-31
US8575174B2 (en) 2013-11-05
US10118907B2 (en) 2018-11-06
KR101879474B1 (ko) 2018-07-17
SMT201600383B (it) 2017-01-10
CY1121514T1 (el) 2020-05-29
US20120322811A1 (en) 2012-12-20
IL229640A0 (en) 2014-01-30
HRP20161348T1 (hr) 2016-12-02
HUE030883T2 (en) 2017-06-28
EA201490045A1 (ru) 2014-07-30
ES2601213T3 (es) 2017-02-14
US20220119362A1 (en) 2022-04-21
KR20180075717A (ko) 2018-07-04
KR20140041567A (ko) 2014-04-04
PL3135656T3 (pl) 2019-07-31
US9216961B2 (en) 2015-12-22
US20190031631A1 (en) 2019-01-31
JP5668177B2 (ja) 2015-02-12
US11059798B2 (en) 2021-07-13
CO6821965A2 (es) 2013-12-31
JP2014520140A (ja) 2014-08-21
SI3135656T1 (sl) 2019-05-31
MY196998A (en) 2023-05-17
MX339552B (es) 2016-05-31
CL2013003646A1 (es) 2014-07-04
PL2720989T3 (pl) 2017-05-31
TWI659741B (zh) 2019-05-21
EP2720989B1 (en) 2016-08-10
US20130281436A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
ECSP14013155A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
PE20151065A1 (es) Novedosos derivados de bencimidazol como antagonistas de ep4
CR20150424A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
ECSP14013215A (es) Compuestos novedosos
GT201400196A (es) Compuestos de heterociclilo
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
AR090712A1 (es) Agentes para tratar trastornos que implican la modulacion de receptores de rianodina
NI201500050A (es) Benzamidas
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
CR20140005A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
UY33490A (es) Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos.
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
UY33348A (es) Compuestos de furopiridina y usos de los mismos
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
CU20140007A7 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
AR089590A1 (es) Sal de bromhidrato de pridopidina

Legal Events

Date Code Title Description
FG Grant, registration